Treatment of Idiopathic Pulmonary Fibrosis

被引：14

作者：

Abuserewa, Sherif T. ^{[1
]}

Duff, Richard ^{[2
]}

Becker, Gregory ^{[2
]}

机构：

[1] Grand Strand Reg Med Ctr, Internal Med, Myrtle Beach, SC 29572 USA

[2] Grand Strand Med Ctr, Dept Pulm & Crit Care Med, Myrtle Beach, SC USA

来源：

CUREUS JOURNAL OF MEDICAL SCIENCE | 2021年 / 13卷 / 05期

关键词：

ipf; progressive interstitial lung disease; future management; pulmonary disease; literature review of disease; BILATERAL LUNG TRANSPLANTATION; FORCED VITAL CAPACITY; GASTROESOPHAGEAL-REFLUX; CONTROLLED-TRIAL; OXYGEN-THERAPY; NINTEDANIB; PIRFENIDONE; SURVIVAL; EFFICACY; PREDNISONE;

D O I：

10.7759/cureus.15360

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial pneumonia of unknown cause, occurring in adults and limited to the lungs. In the past, treatment was aimed at minimizing inflammation and slowing the progression of inflammation to fibrosis. However, the underlying lesion in IPF may be more fibrotic than inflammatory, explaining why few patients respond to anti-inflammatory therapies and the prognosis remains poor. In this review of literature, we will be focusing on main lines of treatment including current medications, supportive care, lung transplantation evaluation, and potential future strategies of treatment.

引用

页数：10

共 97 条

[1]

[Anonymous], 2020, INT THORACIC ORGAN T

[2]

[Anonymous], 2019, Highlights of Prescribing Information: Spravato

[3]

[Anonymous], 2014, NINTEDANIB

[4] Honeycomb Lung: History and Current Concepts [J].

Arakawa, Hiroaki ;

Honma, Koichi .

AMERICAN JOURNAL OF ROENTGENOLOGY, 2011, 196 (04) :773-782

[5] Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE) [J].

Behr, Juegen Y. ;

Kolb, Martin ;

Song, Jin Woo ;

Luppi, Fabrizio ;

Schinzel, Birgit ;

Stowasser, Susanne ;

Quaresma, Manuel ;

Martinez, Fernando J. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 200 (12) :1505-1512

[6] Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis [J].

Bonella, Francesco ;

Kreuter, Michael ;

Hagmeyer, Lars ;

Neurohr, Claus ;

Keller, Claus ;

Kohlhaeufl, Martin J. ;

Mueller-Quernheim, Joachim ;

Milger, Katrin ;

Prasse, Antje .

RESPIRATION, 2016, 92 (02) :98-106

[7] Severe hematologic complications after lung transplantation in patients with telomerase complex mutations [J].

Borie, Raphael ;

Kannengiesser, Caroline ;

Hirschi, Sandrine ;

Le Pavec, Jerome ;

Mal, Herve ;

Bergot, Emmanuel ;

Jouneau, Stephane ;

Naccache, Jean-Marc ;

Revy, Patrick ;

Boutboul, David ;

De la Tour, Regis Peffault ;

Wemeau-Stervinou, Lidwine ;

Philit, Francois ;

Cordier, Jean-Francois ;

Thabut, Gabriel ;

Crestani, Bruno ;

Cottin, Vincent .

JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2015, 34 (04) :538-546

[8] Drug Treatment of Idiopathic Pulmonary Fibrosis Systematic Review and Network Meta-Analysis [J].

Canestaro, William J. ;

Forrester, Sara H. ;

Raghu, Ganesh ;

Ho, Lawrence ;

Devine, Beth E. .

CHEST, 2016, 149 (03) :756-766

[9] Treatment of Idiopathic Pulmonary Fibrosis [J].

Carlos, William G. ;

Strek, Mary E. ;

Wang, Tisha S. ;

Patel, Harin ;

Raghu, Ganesh ;

Wilson, Kevin C. ;

Thomson, Carey C. .

ANNALS OF THE AMERICAN THORACIC SOCIETY, 2016, 13 (01) :115-117

[10] Patient experiences with pulmonary fibrosis [J].

Collard, Harold R. ;

Tino, Gregory ;

Noble, Paul W. ;

Shreve, Mark A. ;

Michaels, Maureen ;

Carlson, Bruce ;

Schwarz, Marvin I. .

RESPIRATORY MEDICINE, 2007, 101 (06) :1350-1354

← 1 2 3 4 5 6 7 8 9 10 →